iGlarLixi Fixed-Ratio Combination vs. Insulin Glargine and Lixisenatide in Patients with T2DM Treated Previously with Two Oral Antidiabetics: LixiLan-O Subgroup Analysis

被引：0
|
作者：
Russell-Jones, David
Mccrimmon, Rory J.
Barber, Thomas M.
Baradez, Cecile
Baxter, Michael A.
Davies, Melanie
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
134-LB
引用
收藏
页码：LB35 / LB35
页数：1
相关论文
共 47 条
  • [1] Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial
    Guerci, B.
    Davies, M.
    Leiter, L. A.
    Grunberger, G.
    Ampudia-Blasco, F.
    Yu, C.
    Stager, W.
    Niemoeller, E.
    Souhami, E.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S384
  • [2] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    [J]. DIABETES, 2019, 68
  • [3] Consistent Outcomes across Dose Ranges with Titratable LixiLan, Insulin Glargine/Lixisenatide Fixed-Ratio Combination, in the LixiLan-O Trial
    Henry, Robert R.
    Ahren, Bo
    Davies, Melanie
    Wu, Yujun
    Handelsman, Yehuda
    Souhami, Elisabeth
    Niemoeller, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES, 2016, 65 : A264 - A264
  • [4] Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin Glargine and Lixisenatide in the LixiLan-O Trial
    Davies, Melanie
    Leiter, Lawrence A.
    Grunberger, George
    Ampudia-Blasco, F. Javier
    Guerci, Bruno
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES, 2016, 65 : A268 - A268
  • [5] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The Lixi-Lan-L Trial
    Aroda, Vanita
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Galvez, Guillermo Gonzalez
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES, 2016, 65 : A62 - A63
  • [6] Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial
    Rosenstock, J.
    Aronson, R.
    Hanefeld, M.
    Piatti, P.
    Serusclat, P.
    Cheng, X.
    Zhou, T.
    Niemoeller, E.
    Souhami, E.
    Grunberger, G.
    Davies, M.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S385
  • [7] Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Grunberger, George
    Hanefeld, Markolf
    Piatti, PierMarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Davies, Melanie
    [J]. DIABETES CARE, 2016, 39 (11) : 2026 - 2035
  • [8] iGlarLixi Fixed-Ratio Combination in Patients with HbA1c >9%: LixiLan-O Subgroup Analysis
    Davies, Melanie
    Russell-Jones, David
    Barber, Thomas M.
    Baradez, Cecile
    Baxter, Michael A.
    Mccrimmon, Rory J.
    [J]. DIABETES, 2017, 66 : LB36 - LB36
  • [9] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    [J]. DIABETES, 2014, 63 : A87 - A88
  • [10] Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
    Davies, Melanie J.
    Leiter, Lawrence A.
    Guerci, Bruno
    Grunberger, George
    Javier Ampudia-Blasco, F.
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1798 - 1804
12345